Publication date: Jan 16, 2025
This clinical trial is a prospective, multicenter, open-label, randomized, actively controlled, parallel-group Phase 3 clinical trial to evaluate the efficacy, safety and tolerability of treatment with IMA203 administered at the recommended phase 2 dose versus investigator’s choice of treatment in patients with previously treated, unresectable or metastatic cutaneous melanoma.
Semantics
| Type | Source | Name |
|---|---|---|
| disease | MESH | Melanoma |
| pathway | KEGG | Melanoma |
| disease | MESH | Disease progression |
| disease | MESH | Tumors |
| disease | MESH | uveal melanoma |
| disease | MESH | squamous cell carcinoma |
| disease | MESH | carcinoma in situ |
| disease | MESH | autoimmune disease |
| disease | MESH | hypersensitivity |
| disease | MESH | contraindications |
| disease | MESH | HIV infection |
| pathway | REACTOME | HIV Infection |
| disease | MESH | infection |
| disease | MESH | psychiatric disorders |
| disease | MESH | substance dependence |
| disease | MESH | ascites |
| disease | MESH | pericardial effusion |
| disease | MESH | brain metastases |
| disease | MESH | Melanoma Cutaneous Malignant |
Original Article
(Visited 1 times, 1 visits today)